QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS Russian patent published in 2020 - IPC C07D471/04 C07D487/04 A61K31/496 A61K31/519 A61P35/00 

FIELD: organic chemistry.

SUBSTANCE: invention relates to a heterocyclic compound of formula (III) and/or a pharmaceutically acceptable salt thereof, where J is N; J' is CR¹, where R¹ is hydrogen; Ar is phenyl substituted with three or four substitutes independently selected from C₁-C₆ alkoxy and halogen; R² is C₁-C₆ alkyl, C₂-C₆ alkynyl, halogen-C₁-C₆ alkyl, C₃-C₆ cycloalkyl, optionally substituted with hydroxy-group; C₃-C₆ cycloalkyl-C₁ alkyl, hydroxy-C₁-C₆ alkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₄-C₆ heterocyclyl containing one heteroatom selected from O; or C₅-C₆ heterocyclyl-C₁-C₂ alkyl containing one or two heteroatoms selected from N or O; Q represents C₁-C₃ alkylene or C₁-C₃ alkylene substituted with two methyl; and X represents a group of formula (a), wherein R³ represents hydrogen or C₁-C₆ alkyl; and R⁴ denotes hydrogen or C₁-C₆ alkyl; Y is -CO-; R^c is hydrogen or C₁-C₆ alkyl; and R^d is hydrogen. Invention also relates to specific compounds of formula (III) and a pharmaceutical composition based on the compound of formula (III).

EFFECT: obtaining novel heterocyclic compounds useful as fibroblast growth factor receptor (FGFR) inhibitor, and therefore also useful for treating cancer.

14 cl, 3 dwg, 2 tbl, 162 ex